TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04945525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Continuity Program
Description: The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
Study: NCT05843331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implants
Description: Four implants in the maxilla with locator attachments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implants
Description: Four implants in the maxilla with locator attachments
Study: NCT06432400

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: Patients questionnaires, on paper and data collection on patients medical file
Study: NCT06286332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: 30 minutes of self-selected music playback every day.
Study: NCT06460870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mojzisova method
Description: The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
Study: NCT04679038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Intravenous (IV) on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib, po, qd
Study: NCT04524221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-100
Description: PTG-100, 600mg taken twice daily in capsule form for 42 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice daily in capsule form for 42 days
Study: NCT05086965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing the virtual game simulation
Description: The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
Study: NCT05672368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Surgery
Description: Undergo surgery using the da Vinci SP device
Study: NCT05461586

Intervention type: DEVICE
Intervention: Refractive Technique (MR #1)
Description: Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.

Intervention type: DEVICE
Intervention: Refractive Technique (MR #1)
Description: Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.

Intervention type: DEVICE
Intervention: Refractive Technique (MR #2)
Description: Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths

Intervention type: DEVICE
Intervention: Refractive Technique (MR #2)
Description: Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
Study: NCT05177042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-110 in Combination with Abiraterone
Description: ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
Study: NCT06059807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: maxillary expansion
Description: Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: maxillary expansion
Description: Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
Study: NCT04690218

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital anxiety and depression scale
Description: Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital anxiety and depression scale
Description: Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index
Description: Self assessment scale for public community. Applying the scale does not require any specially trained personnel.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index
Description: Self assessment scale for public community. Applying the scale does not require any specially trained personnel.

Intervention type: BEHAVIORAL
Intervention: Nutritional Status Questionnaire
Description: It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.

Intervention type: BEHAVIORAL
Intervention: Nutritional Status Questionnaire
Description: It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
Study: NCT04839536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane inhalant product
Description: Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
Study: NCT05220241

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab for RT-PCR SARS-CoV-2
Description: 2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab for RT-PCR SARS-CoV-2
Description: 2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
Study: NCT04886518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitolisant Oral Tablet
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitolisant Oral Tablet
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study: NCT05725330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification and education with mobile game application
Description: This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
Study: NCT04771143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for oral administration
Study: NCT05694663

Intervention type: DEVICE
Intervention: Vivistim
Description: After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
Study: NCT05807412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA-Xvfs
Description: All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim.
Study: NCT06208683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, inactivated, quadrivlent(QIV)
Description: 0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, inactivated, quadrivlent(QIV)
Description: 0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
Study: NCT05844228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT04930315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: 200mg, iv, d1, q2w, both in two groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, iv, d1, q2w, both in two groups
Study: NCT05468281

Intervention type: OTHER
Intervention: Checklist implementation
Description: . Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
Study: NCT05302427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Massage
Description: The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
Study: NCT03856736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIAT
Description: Moderated aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIAT
Description: Moderated aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Weekly body relaxation and sham group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Weekly body relaxation and sham group
Study: NCT04618029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Modification
Description: Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home
Study: NCT06462287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 and 80Mg Oral Capsule
Description: Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:1 oral capsule time a day for 4 days
Study: NCT04758481

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: primary tumour radiotherapy
Description: The study subjects will undergo primary tumour radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: The study subjects will undergo stereotactic body radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: maintenance radiotherapy
Description: The study subjects will undergo maintenance radiotherapy.
Study: NCT05938348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: angiopuncture
Description: we conducted acupuncture on perforators by using acupuncture needles.
Study: NCT05654220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
Study: NCT05985837

Intervention type: DEVICE
Intervention: KalobaGOLA spray (1)
Description: Oral spray, 2-4 spray, till 8 times per day

Intervention type: DEVICE
Intervention: KalobaGOLA spray (1)
Description: Oral spray, 2-4 spray, till 8 times per day

Intervention type: DEVICE
Intervention: KalobaGOLA spray (2)
Description: Oral spray, 2-4 spray, till 4 times per day

Intervention type: DEVICE
Intervention: KalobaGOLA tablets
Description: 1 tablets, 6 times per day

Intervention type: DEVICE
Intervention: KalobaGOLA tablets
Description: 1 tablets, 6 times per day
Study: NCT05163301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Intervention
Description: 2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Intervention
Description: 2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
Study: NCT06375395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS Device
Description: Transcranial Alternating Current Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tACS Device
Description: Placebo Device that simulates active tACS treatment
Study: NCT05280821

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: daily ferrous sulfate
Description: Daily intake of 100 mg ferrous sulfate capsules for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alternate day ferrous sulfate
Description: Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
Study: NCT05543642

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Vaccination series administered to prevent hepA infection.
Study: NCT05663463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose - 2 doses
Description: 2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High-Dose - 1 dose of HD
Description: 1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
Study: NCT00988793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal pancreatectomy
Description: Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open distal pancreatectomy
Description: Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
Study: NCT05257928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-CITE Gait
Description: The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
Study: NCT05543642

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Vaccination series administered to prevent hepA infection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, pertussis, and tetanus booster vaccine
Description: Vaccination booster administered to prevent diphtheria, pertussis, and tetanus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, pertussis, and tetanus booster vaccine
Description: Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
Study: NCT05822154

Intervention type: OTHER
Intervention: comprehensive geriatric assessment
Description: The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
Study: NCT05036161

Intervention type: OTHER
Intervention: Nasal high flow
Description: Newborns with respiratory distress treated with NHF.

Intervention type: OTHER
Intervention: Continuous Positive Airway Pressure
Description: Newborns with respiratory distress treated with CPAP.
Study: NCT05575700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg tablet three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet three times daily
Study: NCT05628155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral diet including n-3 PUFA intake
Description: menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
Study: NCT05251298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordination through the online platform JamesAKTIV
Description: Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment
Study: NCT06271694

Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular Rehabilitation
Description: Standard vestibular rehabilitation
Study: NCT06197737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Interval Training
Description: Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: sprint interval training in which they will do stair climbing 3 times a week with a fast pace.